Screener
Palvella Therapeutics PVLA Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 31,446 | 31,576 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 14,313,659 and 12,380,933 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 14 | 12 |
| Additional paid-in capital | 383,421 | 163,338 |
| Accumulated other comprehensive (loss) income | 95 | 83 |
| Accumulated deficit | (151,217) | (135,450) |
| Total stockholders’ equity | 232,313 | 27,983 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's common stock?
- Palvella Therapeutics (PVLA) reported common stock of $14K in Q1 2026.
- How has Palvella Therapeutics's common stock changed year-over-year?
- Palvella Therapeutics's common stock increased by 27.3% year-over-year, from $11K to $14K.
- What is the long-term trend for Palvella Therapeutics's common stock?
- Over 5 years (2020 to 2025), Palvella Therapeutics's common stock has grown at a -26.5% compound annual growth rate (CAGR), from $56K to $12K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Palvella Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude